Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500698 | 0.75 | TSHR (0.55) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL4060148 | 0.73 | TSHR (0.52) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL2026871 | 0.71 | TSHR (0.50) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL575207 | 0.69 | TSHR (0.52) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL2878616 | 0.68 | TSHR (0.38) | TSHRTP53TDP1PPARD | |
| SCHEMBL2780506 | 0.68 | TSHR (0.46) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL5160811 | 0.67 | TSHR (0.40) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL27819068 | 0.65 | PPARD (0.52) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL21428725 | 0.65 | TSHR (0.48) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL29739400 | 0.65 | TSHR (0.48) | TSHRTP53TDP1PPARDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120965-B1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | claimed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | claimed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | claimed |
| EP-2120965-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | Novabay Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008083347-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| EP-2120965-B1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| EP-2120965-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | Novabay Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008083347-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | DCTD, DDC, DAO | TSHR 2863/4885TP53 1202/4885TDP1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.